Direct effect of GLP-1 infusion on endogenous glucose production in humans

Diabetologia

Volumn 56, Issue 1, 2013, Pages 156-161

  Seghieri, M ^a   Rebelos, E ^a   Gastaldelli, A ^b   Astiarraga, B D ^a   Casolaro, A ^a   Barsotti, E ^a   Pocai, A ^c   Nauck, M ^d   Muscelli, E ^a   Ferrannini, E ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

^d DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

Endogenous glucose production; GLP 1; Liver glucose output; Pancreatic clamp

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCEROL; INSULIN; SODIUM CHLORIDE; SOMATOSTATIN;

ADULT; ARTICLE; CALORIMETRY; CONTROLLED STUDY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; LIPOLYSIS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VOLUNTEER;

ADULT; BLOOD GLUCOSE; CALORIMETRY, INDIRECT; CROSS-OVER STUDIES; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCONEOGENESIS; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLYCEROL; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; LIPOLYSIS; LIVER; MALE; PEPTIDE FRAGMENTS; SYMPATHOMIMETICS; UP-REGULATION; YOUNG ADULT;

EID: 84871564295     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2738-3     Document Type: Article

References (29)

1. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439 (Pubitemid 350041474)
2. Körner M, Stöckli M, Waser B, Reubi JC (2007) GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48:736-743 (Pubitemid 47604973)
3. Gupta NA, Mells J, Dunham RM et al. (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51:1584-1592
4. Svegliati-Baroni G, Saccomanno S, Rychlicki C et al. (2011) Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 31:1285-1297
5. Wang Y, Kole HK, Montrose-Rafizadeh C, Perfetti R, Bernier M, Egan JM (1997) Regulation of glucose transporter and hexose up-take in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions. J Mol Endocrinol 19:241-248 (Pubitemid 28023159)
6. Villanueva-Peñacarrillo ML, Martín-Duce A, Ramos-Álvarez I et al. (2011) Characteristics of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients. Regul Pept 7:39-44
7. Vahl TP, Tauchi M, Durler TS et al. (2007) Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148:4965-4973 (Pubitemid 47481523)
8. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ (1994) Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 43:104-108 (Pubitemid 24047112)
9. Larsson H, Holst JJ, Ahrén B (1997) Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160:413-422 (Pubitemid 27342031)
10. Toft-Nielson M, Madsbad S, Holst JJ (1996) The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556 (Pubitemid 26140536)
11. Orskov C, Wettergren A, Holst JJ (1993) Biological effects and metabolic rates of glucagon-like peptide-1 7-36 amide and glucagon-like peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661 (Pubitemid 23127154)
12. Prigeon RL, Quddusi S, Paty B, D'Alessio DA (2003) Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285:E701-E707
13. Shalev A, Ninnis R, Keller U (1998) Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Horm Res 49:221-225 (Pubitemid 28165739)
14. Egan JM, Menelly GS, Habener JF, Elahi D (2002) Glucagon-like peptide-1 augments insulin mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87:3768-3773 (Pubitemid 34879525)
15. Menelly GS, McIntosh CH, Pederson RA et al. (2001) Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24:1951-1956 (Pubitemid 33716507)
16. Sancho V, Trigo MV, Martín-Duce A et al. (2006) Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med 17:1133-1137
17. Bertin E, Arner P, Bolinder J, Hagström-Toft E (2001) Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab 86:1229-1234 (Pubitemid 32323009)
18. Knauf C, Cani PD, Perrin C et al. (2005) Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115:3554-3563 (Pubitemid 43121843)
19. Bharucha AE, Charkoudian N, Andrews CN et al. (2008) Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 295:R874-R880
20. Muscelli E, Casolaro A, Gastaldelli A et al. (2012) Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 97:2818-2826
21. Gastaldelli A, Coggan AR, Wolfe RR (1999) Assessment of methods for improving tracer estimation of non-steady-state rate of appearance. J Appl Physiol 87:1813-1822
22. Steele RW, Wall JS, de Bodo RC, Altszuler N (1956) Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15-24
23. Ferrannini E (1998) The theoretical bases of indirect calorimetry: a review. Metabolism 37:287-301
24. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA (2000) Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49:611-617 (Pubitemid 30183750)
25. Vella A, Shah P, Basu R et al. (2001) Effect of glucagon-like peptide 1(7-36) amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes 50:565-572 (Pubitemid 32195221)
26. Tomas E, Stanojevic V, Habener JF (2011) GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 167:177-184
27. Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ (2009) The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 150:1155-1164
28. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A (1996) A vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271:E808-E813
29. Johnson KM, Edgerton DS, Rodewald T et al. (2007) Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am J Physiol Endocrinol Metab 293:E1085-E1091 (Pubitemid 47535841)